These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Tumor progression in vitro: the paradoxical natural antibody and complement-selected phenotype.
    Author: Chow DA, Chan J.
    Journal: Nat Immun Cell Growth Regul; 1987; 6(4):189-204. PubMed ID: 3683415.
    Abstract:
    An in vitro model of tumor progression was employed to investigate the contribution of natural antibody (NAb) to antitumor resistance in vivo. Repeated cycles of L5178Y-F9 and SL2-5 tumor growth in the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) followed by the selective elimination of sensitive variants through complement-dependent syngeneic NAb lysis yielded tumors with a reduced sensitivity to NAb and complement, natural killer (NK) cells and the rapid elimination assay of natural resistance (NR). A dissection of the resistant phenotype revealed a reduction in the binding capacity of complement-fixing NAb and NK cells, a reduced susceptibility to hypotonic lysis and, paradoxically, increased fluorescence-detected NAb binding that correlated inversely with a reduced tumor frequency of threshold subcutaneous tumor inocula. The data distinguish tumor binding of NAb that leads to complement activation from other NAb binding and expose a difference between NR measured as the tumor frequency of threshold tumor inocula versus the rapid radiolabelled tumor elimination assay. Complement-dependent NAb lysis may not contribute significantly to the defense against small tumor foci; however, NAb-mediated processes associated with high fluorescence-detected NAb binding likely provide resistance.
    [Abstract] [Full Text] [Related] [New Search]